Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2015 | 3-year update on the ELOQUENT-2 clinical trial of elotuzumab in multiple myeloma

Paul Richardson • 4 Dec 2015
ASH 2015
Multiple Myeloma Antibodies Dexamethasone Elotuzumab Lenalidomide

Paul Richardson, MD from the Dana-Farber Cancer Institute Medical Oncology, Boston, MA provides an overview of the 3-year update presented at the American Society of Hematology (ASH) 2015 Annual Meeting, on the ELOQUENT-2 clinical trial of elotuzumab in combination with lenalidomide and dex­a­meth­a­sone in multiple myeloma. The study demonstrated a sustained progression-free survival (PFS) benefit to patients in the elotuzumab arm, when compared to placebo in relapsed/refractory myeloma.

More from Paul Richardson

1:35
Novel therapeutic options and quadruplet regimens for newly diagnosed multiple myeloma
Paul Richardson • 29 Sep 2023
2:51
ANCHOR and LIGHTHOUSE trials: melflufen in multiple myeloma
Paul Richardson • 29 Sep 2023
7:24
Session highlights: managing the aging population in myeloma & promising treatment options
Paul Richardson • 29 Sep 2023
2:59
Exploring the potential role of melflufen in myeloma & updates from the LIGHTHOUSE trial
Paul Richardson • 12 May 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals